• Explore /
  • Poster
  • / Phase 2 study of ASTX727 (cedazuridine/decitabine) plus venetoclax (ven) in patients with relapsed/refractory acute myeloid leukemia (AML) or previously untreated, elderly patients (pts) unfit for chemotherapy.

Phase 2 study of ASTX727 (cedazuridine/decitabine) plus venetoclax (ven) in patients with relapsed/refractory acute myeloid leukemia (AML) or previously untreated, elderly patients (pts) unfit for chemotherapy.

Abstract Poster

Authors

null

Farhad Ravandi

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Farhad Ravandi , Tareq Abuasab , Yesid Alvarado Valero , Ghayas C. Issa , Rabiul Islam , Nicholas James Short , Musa Yilmaz , Nitin Jain , Lucia Masarova , Steven Mitchell Kornblau , Elias Jabbour , Naveen Pemmaraju , Guillermo Montalban Bravo , Sherry Pierce , Courtney Denton Dinardo , Tapan M. Kadia , Naval Guastad Daver , Marina Konopleva , Guillermo Garcia-Manero

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Acute Leukemia

Clinical Trial Registration Number

NCT04746235

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 7037)

DOI

10.1200/JCO.2022.40.16_suppl.7037

Abstract #

7037

Poster Bd #

268

Abstract Disclosures

Similar Posters

First Author: Amer Methqal Zeidan

First Author: Koichi Takahashi

First Author: Maha AT Elsebaie

First Author: Muhammad Husnain